Screener
Nuvectis Pharma, Inc. NVCT Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055318
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| TOTAL LIABILITIES | 11,178 | 13,296 |
| COMMITMENTS AND CONTINGENCIES, see Note 3 | ||
| SHAREHOLDERS’ EQUITY, see Note 4 | ||
| Common Shares, $0.00001 par value – 60,000,000 shares authorized as of March 31, 2026, and December 31, 2025, 26,525,533, and 25,676,798 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | * | * |
| Additional paid in capital | 119,957 | 118,100 |
| Accumulated deficit | (105,737) | (99,687) |
| TOTAL SHAREHOLDERS’ EQUITY | 14,220 | 18,413 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $25,398 | $31,709 |
Item 1. Financial Statements
FAQ
- What is Nuvectis Pharma, Inc.'s retained earnings?
- Nuvectis Pharma, Inc. (NVCT) reported retained earnings of -$105.74M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s retained earnings changed year-over-year?
- Nuvectis Pharma, Inc.'s retained earnings decreased by 34.6% year-over-year, from -$78.58M to -$105.74M.
- What is the long-term trend for Nuvectis Pharma, Inc.'s retained earnings?
- Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s retained earnings has grown at a 66.7% compound annual growth rate (CAGR), from -$12.9M to -$99.69M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Nuvectis Pharma, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude